Articles dans des revues avec comité de lecture (16)
  1. 1. Tack, J., Bruyneel, A., Silvio Taccone, F., Thys, F., Melot, C., Van Wilder, P., & Pirson, M. (2024). Analysis of admissions to intensive care units that could be supported on an intermediate care unit. Nursing in critical care. doi:DOI: 10.1111/nicc.13043
  2. 2. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2023). The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis. Health Research Policy and Systems, 21(1), 68. doi:10.1186/s12961-023-01015-4
  3. 3. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., Turk, F., & Huys, I. (2022). Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study. BMC health services research, 22(1), 1211. doi:10.1186/s12913-022-08591-1
  4. 4. Larcin, L., Karakaya, G., Rygaert, X., Van Wilder, P., Lamy, C., Demyttenaere, B., Damase-Michel, C., & Kirakoya, F. (2022). Trends and regional variations in prescriptions dispensed to stimulate uterine contractions at the end of pregnancy in Belgium: A community-based study from 2003 to 2018. Pharmacoepidemiology and drug safety. doi:10.1002/pds.5558
  5. 5. Vandenplas, Y., Barbier, L., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2022). Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology, 12, 789640. doi:10.3389/fphar.2021.789640
  6. 6. Nuijten, M., & Van Wilder, P. (2021). The impact of early phase price agreements on prices of orphan drugs. BMC health services research, 21(1), 222. doi:10.1186/s12913-021-06208-7
  7. 7. Dehanne, F., Gourdin, M., Devleesschauwer, B., Bihin, B., Van Wilder, P., Mareschal, B., Leclercq, P., & Pirson, M. (2021). Cost-DALY comparison of hip replacement care in 12 Belgian hospitals. BMJ open quality, 10(3), 1-11. doi:10.1136/bmjoq-2020-001263
  8. 8. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2021). Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology, 12, 644187. doi:10.3389/fphar.2021.644187
  9. 9. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2021). Informing patients about biosimilar medicines: The role of European patient associations. Pharmaceuticals, 14(2), 117, 1-21. doi:10.3390/ph14020117
  10. 10. Annemans, L., Beutels, P., Bloom, D. D., De Backer, W., Ethgen, O., Luyten, J., Van Wilder, P., Willem, L., & Simoens, S. (2020). Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value in health. doi:10.1016/j.jval.2020.09.005
  11. 11. De Foor, J., Van Wilder, P., Leclercq, P., Martins, D., & Pirson, M. (2019). The hospital cost of hip replacement for old inpatients in Belgium. European Geriatric Medicine, 10(1), 67-78. doi:10.1007/s41999-018-0150-3
  12. 12. Dehanne, F., Leclercq, P., Van Wilder, P., Gourdin, M., & Pirson, M. (2019). Benchmarking of hip prosthesis in 7 hospitals. Journal de gestion et d'économie médicales, 37(5-6), 1-21.
    13. << Précédent 1 2 Suivant >>